In keeping with the focus on the 2013 registry download, here’s new stem cell hand arthritis data, which is the data from a group of patients with mostly severe thumb arthritis who were injected with their own stem cells. Most of these patients would have been candidates for a less than perfect thumb joint replacement (were 40% can suffer complications) or a surgery where a tendon is coiled up in the joint at the base of the thumb. Both are big surgeries with significant complications. Instead they opted for an injection of their own stem cells. This is our smallest data set of the group we’ll be releasing this year and about 1/3 of these patients were treated by our provider network. In general, looking at two small data sets (same day stem cells (Regenexx-SD) vs. cultured stem cells (Regenexx-C)), the cultured cells did seem to outperform the same day cells in patients with severe thumb arthritis (see our published paper on the use of cultured stem cells for hand arthritis). One caution is that since these are both small groups of patients, the trends for which procedure is better could change as more patient data is collected. We’re also looking at some interesting trends in this data which we believe will help us continue to improve outcomes in this group of patients when they’re treated with same day stem cells by adding some additional structures and techniques to the injections.
RegenexxCayman is an independently owned and operated medical services provider operating exclusively in the Cayman Islands and is not part of or affiliated with the Centeno-Schultz Clinic or any U.S. Regenexx Network provider. The Regenexx-C procedure licensed by RegenexxCayman is not approved by the U.S. FDA for use in the United States.